Oscar Health, Inc. (OSCR)
NYSE: OSCR · Real-Time Price · USD
13.84
-0.55 (-3.82%)
At close: Mar 6, 2026, 4:00 PM EST
13.80
-0.04 (-0.29%)
After-hours: Mar 6, 2026, 7:59 PM EST
Oscar Health Stock Forecast
Stock Price Forecast
The 7 analysts that cover Oscar Health stock have a consensus rating of "Hold" and an average price target of $17, which forecasts a 22.83% increase in the stock price over the next year. The lowest target is $11 and the highest is $25.
Price Target: $17 (+22.83%)
Analyst Consensus: Hold
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Oscar Health stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 2 | 3 | 5 | 5 | 5 |
| Sell | 4 | 3 | 2 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Sell → Hold Upgrades $12 → $17 | Strong Sell → Hold | Upgrades | $12 → $17 | +22.83% | Jan 9, 2026 |
| Barclays | Barclays | Sell → Hold Upgrades $13 → $18 | Sell → Hold | Upgrades | $13 → $18 | +30.06% | Jan 5, 2026 |
| Stephens & Co. | Stephens & Co. | Hold Initiates $17 | Hold | Initiates | $17 | +22.83% | Dec 11, 2025 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $13 → $25 | Hold → Buy | Upgrades | $13 → $25 | +80.64% | Nov 26, 2025 |
| Wells Fargo | Wells Fargo | Sell Maintains $14 → $11 | Sell | Maintains | $14 → $11 | -20.52% | Nov 13, 2025 |
Financial Forecast
Revenue This Year
19.16B
from 11.70B
Increased by 63.73%
Revenue Next Year
20.19B
from 19.16B
Increased by 5.40%
EPS This Year
0.57
from -1.69
EPS Next Year
1.31
from 0.57
Increased by 128.97%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 19.9B | 23.4B | |
| Avg | 19.2B | 20.2B | |
| Low | 17.9B | 15.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 70.3% | 21.9% | |
| Avg | 63.7% | 5.4% | |
| Low | 53.1% | -20.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.21 | 1.86 | |
| Avg | 0.57 | 1.31 | |
| Low | -0.62 | -0.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 225.4% | |
| Avg | - | 129.0% | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.